{"id":"naltrexone-tablet-and-placebo-patch","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Hepatotoxicity (at high doses)"}]},"_chembl":{"chemblId":"CHEMBL1201149","moleculeType":"Small molecule","molecularWeight":"377.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naltrexone is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, preventing endogenous and exogenous opioids from activating these receptors. This mechanism reduces the reinforcing effects of opioids and decreases cravings in opioid use disorder. The placebo patch component suggests this was studied as part of a controlled trial design.","oneSentence":"Naltrexone blocks opioid receptors to reduce cravings and reward-seeking behavior, while the placebo patch serves as a control in this combination formulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:38.909Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"},{"name":"Alcohol use disorder"}]},"trialDetails":[{"nctId":"NCT01999114","phase":"PHASE1","title":"The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2012-03","conditions":"ECG Effects","enrollment":328},{"nctId":"NCT00000437","phase":"PHASE4","title":"Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"1997-09-26","conditions":"Alcoholism, Smoking","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revia"],"phase":"marketed","status":"active","brandName":"Naltrexone Tablet and Placebo Patch","genericName":"Naltrexone Tablet and Placebo Patch","companyName":"The Scripps Research Institute","companyId":"the-scripps-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naltrexone is a medication used to treat conditions such as alcoholism and smoking, as indicated by studies on ClinicalTrials.gov. It is administered in the form of a tablet, and has been studied in combination with a placebo patch, among other interventions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}